Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in…
Posts Positive Organic Growth and Adjusted EBITDA1 of 23.5% of Revenue CINCINNATI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Quipt Home…
MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR,…
~ Revenue up 12% Year-over-Year to $25.1 Million ~ ~ Quarter Concluded with Class A Shares Being Added to Russell…
Total Company Revenue increased 8.4% to a quarterly record of $498.2 million in the second quarter of 2025 from $459.7…
Company will announce second quarter 2025 financial results and host a conference call on August 14, 2025 August 08, 2025…
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Basel, August 7, 2025 – Sandoz…
Highest-ever quarterly net income of $1.385 billion, up 16% YoY, reflects the Company's strong performance Board approves interim dividend of…
Continued execution of BioNTech’s oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates…
Business Highlights Company registered its highest-ever first quarter revenue of Rs. 12,539 million on back of strong execution in Engineering…